D.E. Shaw & Co
VYGR icon

D.E. Shaw & Co’s Voyager Therapeutics VYGR Stock Holding History

D.E. Shaw & Co’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Buy
143,992
+45,276
+46% +$172K ﹤0.01% 4175
2026
Q1 		$381K Buy
+98,716
New +$389K ﹤0.01% 3979
2024
Q4 		– Sell
-118,828
Closed -$695K – 4931
2024
Q3 		$695K Sell
118,828
-86,773
-42% -$631K ﹤0.01% 3510
2024
Q2 		$1.63M Sell
205,601
-28,388
-12% -$238K ﹤0.01% 2841
2024
Q1 		$2.18M Sell
233,989
-172,055
-42% -$1.45M ﹤0.01% 2572
2023
Q4 		$3.43M Sell
406,044
-220,079
-35% -$1.6M ﹤0.01% 2237
2023
Q3 		$4.85M Sell
626,123
-321,850
-34% -$2.94M 0.01% 1831
2023
Q2 		$10.9M Buy
947,973
+319,501
+51% +$3.31M 0.01% 1274
2023
Q1 		$4.85M Sell
628,472
-60,228
-9% -$479K 0.01% 1956
2022
Q4 		$4.2M Sell
688,700
-16,076
-2% -$91.3K ﹤0.01% 2256
2022
Q3 		$4.17M Sell
704,776
-22,366
-3% -$143K 0.01% 2293
2022
Q2 		$4.3M Buy
727,142
+90,921
+14% +$614K 0.01% 2317
2022
Q1 		$4.85M Buy
636,221
+342,198
+116% +$1.53M ﹤0.01% 2348
2021
Q4 		$797K Buy
+294,023
New +$1M ﹤0.01% 4102
2020
Q3 		– Sell
-19,927
Closed -$251K – 4195
2020
Q2 		$251K Sell
19,927
-16,776
-46% -$195K ﹤0.01% 3697
2020
Q1 		$336K Sell
36,703
-153,303
-81% -$1.76M ﹤0.01% 3412
2019
Q4 		$2.65M Buy
190,006
+14,620
+8% +$213K ﹤0.01% 2248
2019
Q3 		$3.02M Sell
175,386
-88,076
-33% -$1.85M ﹤0.01% 2052
2019
Q2 		$7.17M Buy
263,462
+22,857
+9% +$523K 0.01% 1331
2019
Q1 		$4.61M Buy
240,605
+201,274
+512% +$2.62M 0.01% 1594
2018
Q4 		$370K Buy
+39,331
New +$505K ﹤0.01% 3256
2017
Q4 		– Sell
-10,621
Closed -$219K – 3759
2017
Q3 		$219K Buy
+10,621
New +$120K ﹤0.01% 3278

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co's VYGR Position: Q2 2026 in Review

D.E. Shaw & Co increased its Voyager Therapeutics (VYGR) stake by 46% in Q2 2026, buying an estimated $172K and bringing the position to 143,992 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #4175.

D.E. Shaw & Co first reported a position in VYGR in Q3 2017 and has held it in 22 quarters since. The position peaked at $10.9M in Q2 2023. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • D.E. Shaw & Co held 143,992 shares of Voyager Therapeutics worth $504K as of Q2 2026.
  • D.E. Shaw & Co bought 45,276 Voyager Therapeutics shares in Q2 2026, an estimated $172K.
  • Voyager Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4175 holding.
  • D.E. Shaw & Co first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 22 quarters since.
  • D.E. Shaw & Co's Voyager Therapeutics position peaked at $10.9M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.